- Quiver Quantitative
- Archive
- Page -33
Archive
Synthetic GLP-1s' popularity is growing and so is their influence on the market
While Eli Lilly & Co and Novo Nordisk are leading the industry, pharmaceutical companies are working overtime to produce biosimilars. How does the increased use of these drugs threaten to disrupt the market across industries?
Margaret Shreiner

